Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of intravitreal etamsylate in age-related macular degeneration
2014-005556-25Phase 2Completed
- Sponsor
- Investigacion Independiente
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of etamsylate in age-related macular degeneration (AMD) and exudative macular degeneration (2 arms), sponsored by Investigacion Independiente. Primary endpoints: Efficacy: visual acuity after prior parent-trial treatment and Efficacy: visual acuity through week 48 with extension treatment. Started Feb 2015; status: completed.
02
Drugs
etamsylate
03
Conditions
age-related macular degeneration (AMD)exudative macular degeneration
Beyond the preview
Go deeper on 2014-005556-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005556-25.